NEXGEL, INC.

NXGL ·Healthcare, Medical Devices, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-3.0M $-3.3M $-3.2M $-4.7M $-4.3M $-2.3M $-1.9M $-1.9M
Depreciation & Amortization $450.0K $436.0K $226.0K $112.0K $113.0K $50.0K $67.0K $322.0K
Depreciation $324.0K $319.0K $132.0K $99.0K $99.0K $42.0K $67.0K
Amortization $126.0K $119.0K $94.0K $13.0K
Stock-Based Compensation $654.0K $367.0K $217.0K $298.0K $285.0K $232.0K $4.0K $0
Net Cash from Operating Activities $-1.3M $-3.9M $-3.2M $-3.0M $-2.8M $-1.8M $-1.8M $-1.5M
Investing Activities
Capital Expenditures $68.0K $443.0K $696.0K $96.0K $269.0K $312.0K $0
Business Acquisitions $500.0K
Net Cash from Investing Activities $-68.0K $-775.0K $4.5M $-5.6M $-269.0K $-312.0K $0
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $630.0K $3.7M $379.0K $-3.7M $16.3M $1.9M $2.1M $1.5M
Net Change in Cash
Free Cash Flow $-1.4M $-4.3M $-3.9M $-3.1M $-3.0M $-2.1M $-1.8M